|
|
100 Fourth Ave N, Ste 600
Seattle, WA 98109 USA
phone:(1) 206 267 3700
fax:
|
|
| Symbol |
Private |
| Founded |
2004 |
| Employees |
47 |
|
|
| www.neurovista.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Technology for the management and treatment of neurological disorders. |
|
| Management |
| John F. Harris, PRESIDENT AND CEO; Kent W. Leyde, CHIEF TECHNOLOGY OFFICER; W. Douglas Sheffield VMD, PhD, VICE PRESIDENT OF CLINICAL RESEARCH; Craig P. Wong, VICE PRESIDENT OF INTELLECTUAL PROPERTY; Hugh H. Matsubayashi, VICE PRESIDENT OF INTELLECTUAL PROPERTY; Mary K. Moore, VICE PRESIDENT OF REGULATORY AFFAIRS; David E. Snyder, VICE PRESIDENT OF NEW TECHNOLOGY; Christine M. Garrison, DIRECTOR OF RECRUITING AND HUMAN RESOURCES; Melinda R. Elwood, DIRECTOR OF QUALITY
|
| |
|
|
| |
|
| Keywords |
| neurology, epilepsy, patient monitoring |
|
|
|
| Description |
|
NeuroVista Corporation is an early-stage medical device company developing technologies for the management and treatment of epilepsy. The company's implantable "early-warning" system for epileptic patients can identify physiological signals associated with the likelihood of an upcoming seizure. |
|
| Market / Customers |
Epilepsy is a neurological condition affecting approximately 1% of the U.S. population - more than Parkinson's disease, multiple sclerosis and Lou Gehrig's disease combined.
|
|
| Status |
| The company received $33.8 million in Series B financing in 2007, which funds research and development endeavors. It plans to conduct its first feasibility trial in 2009; the subsequent pivotal trial can lead to FDA approval of its technology. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members